OBJECTIVE: Studies of cancer screening have found that false positive screening events (FPSE) can affect worry about cancer risk and screening program use, we sought to further explore this. METHOD: In a study of 1,100 women at high risk for ovarian cancer who participated in a previously published randomized controlled trial (RCT), we sought to explore whether worry might also influence the use of risk-reducing surgical procedures by women. Participants included 234 women with BRCA1/2 mutations and 866 women with high-risk pedigrees. We followed the women for up to 6 years. RESULTS: Worry predicted risk reducing prophylactic bilateral salpingo-oophorectomy (pBSO) for both mutation carriers (HR = 1.74; p = .02), and women with high-risk pedigree (HR = 3.41; p < .001). FPSE also predicted subsequent pBSO among women with a high-risk pedigree (HR 2.31; p < .01). While screening may reduce worry among those who never receive a positive result, FPSE increase worry at least temporarily. Worry about ovarian cancer risk predicted use of preventative pBSO among high-risk women including those with BRCA1/2 mutations enrolled in an ovarian cancer-screening program. FPSE also predicted risk-reducing ovarian surgery among high-risk women without a known mutation at the time of screening program enrollment. CONCLUSIONS: Physicians who offer screening should know that false positive results may increase use of pBSO, how this should effect clinical practice is unclear. (PsycINFO Database Record (c) 2018 APA, all rights reserved).
OBJECTIVE: Studies of cancer screening have found that false positive screening events (FPSE) can affect worry about cancer risk and screening program use, we sought to further explore this. METHOD: In a study of 1,100 women at high risk for ovarian cancer who participated in a previously published randomized controlled trial (RCT), we sought to explore whether worry might also influence the use of risk-reducing surgical procedures by women. Participants included 234 women with BRCA1/2 mutations and 866 women with high-risk pedigrees. We followed the women for up to 6 years. RESULTS: Worry predicted risk reducing prophylactic bilateral salpingo-oophorectomy (pBSO) for both mutation carriers (HR = 1.74; p = .02), and women with high-risk pedigree (HR = 3.41; p < .001). FPSE also predicted subsequent pBSO among women with a high-risk pedigree (HR 2.31; p < .01). While screening may reduce worry among those who never receive a positive result, FPSE increase worry at least temporarily. Worry about ovarian cancer risk predicted use of preventative pBSO among high-risk women including those with BRCA1/2 mutations enrolled in an ovarian cancer-screening program. FPSE also predicted risk-reducing ovarian surgery among high-risk women without a known mutation at the time of screening program enrollment. CONCLUSIONS: Physicians who offer screening should know that false positive results may increase use of pBSO, how this should effect clinical practice is unclear. (PsycINFO Database Record (c) 2018 APA, all rights reserved).
Authors: C D Hough; C A Sherman-Baust; E S Pizer; F J Montz; D D Im; N B Rosenshein; K R Cho; G J Riggins; P J Morin Journal: Cancer Res Date: 2000-11-15 Impact factor: 12.701
Authors: M Schummer; W V Ng; R E Bumgarner; P S Nelson; B Schummer; D W Bednarski; L Hassell; R L Baldwin; B Y Karlan; L Hood Journal: Gene Date: 1999-10-01 Impact factor: 3.688
Authors: Joanna B Madalinska; Judith Hollenstein; Eveline Bleiker; Marc van Beurden; Heiddis B Valdimarsdottir; Leon F Massuger; Katja N Gaarenstroom; Marian J E Mourits; René H M Verheijen; Eleonora B L van Dorst; Hans van der Putten; Ko van der Velden; Henk Boonstra; Neil K Aaronson Journal: J Clin Oncol Date: 2005-08-29 Impact factor: 44.544
Authors: Ingegerd Hellström; John Raycraft; Martha Hayden-Ledbetter; Jeffrey A Ledbetter; Michèl Schummer; Martin McIntosh; Charles Drescher; Nicole Urban; Karl Erik Hellström Journal: Cancer Res Date: 2003-07-01 Impact factor: 12.701
Authors: M Robyn Andersen; Judy Nelson; Sue Peacock; Antoinette Giedzinska; Charles Dresher; Deborah Bowen; Nicole Urban Journal: Am J Med Genet A Date: 2004-08-30 Impact factor: 2.802
Authors: Sian Z Williamson; Rebecca Johnson; Harbinder K Sandhu; David R Ellard; Jacquie Jenkins; Margaret Casey; Olive Kearins; Sian Taylor-Phillips Journal: BMJ Open Date: 2019-11-07 Impact factor: 2.692